Home > Boards > US Listed > Medical - Healthcare > Gilead Sciences, Inc. (GILD)

Thanks very much...It's good to see CEO Daniel

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (3) | Next 10 | Previous | Next
LionsTact Member Profile
 
Followed By 39
Posts 4,273
Boards Moderated 0
Alias Born 01/21/14
160x600 placeholder
Gilead's Magrolimab Gets FDA Breakthrough Therapy Designation in Myelodysplastic Syndrome Dow Jones News - 9/15/2020 8:54:00 AM
Gilead’s Magrolimab, an Investigational Anti-CD47 Monoclonal Antibody, Receives FDA Breakthrough Therapy Designation for Tr... Business Wire - 9/15/2020 8:00:00 AM
Hospitalized Covid-19 Patients Recovered Faster With Arthritis Drug Dow Jones News - 9/14/2020 11:26:00 AM
Immunomedics Shares More Than Double After Gilead Deal Dow Jones News - 9/14/2020 8:26:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/14/2020 8:02:48 AM
Gilead Acquires Cancer-Drug Maker -- WSJ Dow Jones News - 9/14/2020 3:02:00 AM
Gilead Reaches Deal to Buy Immunomedics for $21 Billion -- 5th Update Dow Jones News - 9/13/2020 9:01:00 PM
Gilead Reaches Deal to Buy Immunomedics for $21 Billion--4th Update Dow Jones News - 9/13/2020 4:29:00 PM
Gilead Sciences to Acquire Immunomedics Business Wire - 9/13/2020 3:00:00 PM
Gilead Nears Deal to Buy Immunomedics for More Than $20 Billion--3rd Update Dow Jones News - 9/12/2020 4:01:00 PM
Gilead Nears Deal to Buy Immunomedics for More Than $20 Billion--2nd Update Dow Jones News - 9/12/2020 3:50:00 PM
Gilead Nears Deal to Buy Immunomedics for More Than $20 Billion--Update Dow Jones News - 9/12/2020 3:39:00 PM
Gilead Nears Deal to Buy Immunomedics for More Than $20 Billion Dow Jones News - 9/12/2020 3:22:00 PM
Kite Submits Supplemental Biologics License Application to U.S. Food & Drug Administration for Yescarta® in Relapsed or Refr... Business Wire - 9/4/2020 8:30:00 AM
Gilead's Kite Forms AML Collaboration With HiFiBiO Therapeutics Dow Jones News - 9/3/2020 8:56:00 AM
Kite and HiFiBiO Therapeutics Partner to Discover Novel Targets and Antibodies Against Acute Myeloid Leukemia Business Wire - 9/3/2020 8:00:00 AM
Jounce Therapeutics Shares Up 54% After License Agreement With Gilead Dow Jones News - 9/1/2020 10:21:00 AM
Gilead, Jounce In License Agreement for Immunotherapy Program Dow Jones News - 9/1/2020 9:19:00 AM
Gilead Sciences and Jounce Therapeutics Announce Exclusive License Agreement for Novel Immunotherapy Program GlobeNewswire Inc. - 9/1/2020 8:30:10 AM
Gilead Sciences and Jounce Therapeutics Announce Exclusive License Agreement for Novel Immunotherapy Program Business Wire - 9/1/2020 8:30:00 AM
Gilead Says Veklury Gets EUA From FDA to Treat Patients With Moderate Covid-19 Dow Jones News - 8/28/2020 5:42:00 PM
Gilead’s Investigational Antiviral Veklury® (Remdesivir) Receives U.S. Food & Drug Administration Emergency Use Authorizat... Business Wire - 8/28/2020 4:45:00 PM
Gilead Announces Presentation of More Than 40 Abstracts From Extensive Liver Disease Programs at the Digital International Li... Business Wire - 8/25/2020 2:00:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 8/19/2020 12:53:49 PM
Galapagos, Gilead Shares Fall as FDA Seeks More Filgotinib Data Dow Jones News - 8/19/2020 8:24:00 AM
LionsTact   Thursday, 05/28/20 11:12:06 AM
Re: Tha Part Time Er post# 3915
Post # of 4372 
Thanks very much...It's good to see CEO Daniel O’Day collaborating with former employer Roche Holding AG on giving Covid-19 a " Double Tap "... aka " A One-Two Punch "

....(imo) It's a positive step towards full FDA approval as Roche Holding AG likely feels confident with Remdesivir's Phase 3 trials as a 2nd wave hits South Korea and Brazil reaches grim milestones daily.

Roche's Actemra is used to treat inflammatory diseases and to control the cytokine storms associated with certain immuno-oncology treatments.

Gilead’s remdesivir is an antiviral drug. COVID-19 is marked by several unusual symptoms, including blood clotting, cytokine storms and severe pneumonia.

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (3) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences